entecavir and HCC risk

[stef2011]

J Viral Hepat. 2015 Feb;22(2):118-25. doi: 10.1111/jvh.12283. Epub 2014 Jul 15.
Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort.
Papatheodoridis GV1, Manolakopoulos S, Touloumi G, Nikolopoulou G, Raptopoulou-Gigi M, Gogos C, Vafiadis-Zouboulis I, Karamanolis D, Chouta A, Ilias A, Drakoulis C, Mimidis K, Ketikoglou I, Manesis E, Mela M, Hatzis G, Dalekos GN; HepNet.Greece Study Group.
Author information
Abstract
Hepatocellular carcinoma (HCC) may still develop in chronic hepatitis B (CHB) patients treated with lamivudine. Whether HCC rates are comparable in patients treated with the current first-line antivirals remains uncertain. We estimated the incidence and evaluated predictors of HCC in a large nationwide prospective cohort (HepNet.Greece) of HBeAg-negative CHB patients treated with entecavir. HBeAg-negative CHB patients from the same cohort who were initially treated with lamivudine were used as controls. We included 321 patients treated with entecavir for a median of 40 months and 818 patients treated initially with lamivudine for a median of 60 months. In the entecavir group, HCC developed in 4 of 321 (1.2%) patients at a median of 1.5 (range: 1.0-4.5) years, while the cumulative HCC incidence was significantly higher in cirrhotics than noncirrhotics (1, 3, 5 years: 0%, 3%, 9% vs 1%, 1%, 1%; P = 0.024) and in older patients (P = 0.026). Entecavir compared with lamivudine group patients had lower HCC incidence (1, 3, 5 years: 0.3%, 1.2%, 2.8% vs 0.7%, 3.8%, 5.6%; P = 0.024). However, in multivariable Cox regression analysis, the HCC risk was independently associated with older age (P < 0.001), male gender (P = 0.011) and cirrhosis (P = 0.025), but not with the initial agent. In conclusion, our large nationwide study indicates that the HCC risk remains increased in entecavir-treated HBeAg-negative CHB patients with cirrhosis, particularly of older age, at least for the first 5 years. The HCC risk does not seem to be significantly reduced with entecavir compared with antiviral therapy starting with lamivudine.
© 2014 John Wiley & Sons Ltd.
KEYWORDS:
cirrhosis; entecavir; hepatitis B; hepatocellular carcinoma; lamivudine

[flyinsky]

http://www.drugs.com/sfx/viread-side-effects.html
What do You think of This?

[stef2011]

tdf has no tumors in animals and over 14years use on humans, we can confirm it is not dangerous as cancer risk.i hope they keep monitoring hcc risk on tdf trials even when patent is lost which is quite close in a couple of years

while etv is suspected from the start since it did make tumors on mice and under special observation for cancer (they could approve it this way) so the fact that it does not lower HCC risk vs a stupid/weak antiviral like lam is very alarming.i would personally avoid it

[flyinsky]

Ok you insist on tdf maybe it also in near future will show dangerous side effects in long term of use because I think it is some how recent and it is used on HIV patients so the use of viread on hbv didn t take yet a long period of use..but at the moment we are obliged to take it because we haven't other choice and hope that Scientifics don't tell us in 10years viread make cancer of x organ

[stef2011]

not yet i need to confirm doses/responses, too early to tell exactly what worked and dose but anyway my experience simply confirms what i suggest and post.
i of course applied to me the studies i post

[stef2011]

some questions are not in interrogative form...i mean the answer is quite obvious

[stef2011]

questions even more revealing:

why is etv prefered over tdf by most hepatologists?why etv costs more than double tdf?why patent was illegal?why the drug development was not stopped when mice developed lung cancer knowing tdf was the most potent at a research and development level?why was tdf demonized with untrue sides effects to justify its prescription over tdf?